Inceptua to distribute Portola's Ondexxya

7 February 2020

Luxembourg-based Inceptua and US biotech Portola Pharmaceuticals (Nasdaq: PTLA) – a developer and manufacturer of therapeutic agents focusing on thrombosis and other hematological conditions – have entered into an agreement whereby Inceptua will become Portola’s exclusive distribution partner for Ondexxya (andexanet alfa) in selected countries.

Financial terms of the agreement have not been disclosed.

Ondexxya has been approved by the US Food and Drug Administration in 2018 under the trade name AndexXa, and was also cleared by the European Medicines Agency on April 26, 2019. It became the first and only reversal agent approved for adult patients treated with the Factor Xa inhibitors rivaroxaban (Bayer’s [BAYN: DE] Xarelto, or apixaban (Eliquis from Bristol-Myers Squibb [NYSE: ABY]), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK